CD274 and neoplasm: We show that combination PRMT5/PD-L1 inhibition may achieve a better antitumor effect: targeting PRMT5 to directly inhibit tumor cell survival and targeting PD-L1 to overcome the side effects of targeting PRMT5 and enhance immune function.